TP53 mutations and relevance of expression of TP53 pathway genes in paediatric acute myeloid leukaemia. (6th October 2019)

• Record Type: Journal Article
• Authors: Cucchi, David G. J.; Bachas, Costa; Klein, Kim; Huttenhuis, Sander; Zwaan, Christian M.; Ossenkoppele, Gert J.; Janssen, Jeroen M. W. M.; Kaspers, Gertjan L.; Cloos, Jacqueline
• Is Part Of: British journal of haematology. Volume 188:Number 5(2020)
• Page Start: 736
• Page End: 739
• Publication Date: 2019-10-06
• Subjects: acute myeloid leukaemia -- TP53 -- RRM2B; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.16229
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: Limited data are available on the incidence and impact of TP53 alterations and TP53 pathway deregulation in paediatric acute myeloid leukaemia (AML). We analysed TP53 alterations in bone marrow samples of 229 patients with de novo paediatric AML, and detected heterozygous missense exon mutations in two patients (1%) and 17p deletions of the TP53 gene in four patients (2%). These patients more frequently had complex karyotype (50% vs. 4%, P = 0·002) or adverse cytogenetic abnormalities, including complex karyotype (67% vs. 17%, P = 0·013), compared to TP53 wild‐type. Differential expression of TP53 pathway genes was associated with poor survival, indicating a role for TP53 regulators and effector genes.